Jeffrey Zwicker

Posts

The safety of DOACs to treat VTE in patients with brain tumors
Anticoagulation Drugs

The safety of DOACs to treat VTE in patients with brain tumors

Patients with primary and metastatic brain tumors have a high risk of venous thromboembolism, occurring in 20-30% depending on primary tumor type. Anticoagulant therapy for patients with brain tumors is challenging given concerns regarding risk of clinically significant intracranial hemorrhage, which occurs at a rate of between 2-20% in patients not receiving anticoagulation [3-4].

Read More